Cargando…

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts

BACKGROUND: Management of advanced chordomas remains delicate considering their insensitivity to chemotherapy. Homozygous deletion of the regulatory gene CDKN2A has been described as the most frequent genetic alteration in chordomas and may be considered as a potential theranostic marker. Here, we e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passeri, Thibault, Dahmani, Ahmed, Masliah-Planchon, Julien, El Botty, Rania, Courtois, Laura, Vacher, Sophie, Marangoni, Elisabetta, Nemati, Fariba, Roman-Roman, Sergio, Adle-Biassette, Homa, Mammar, Hamid, Froelich, Sébastien, Bièche, Ivan, Decaudin, Didier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732546/ https://www.ncbi.nlm.nih.gov/pubmed/36505864 http://dx.doi.org/10.3389/fonc.2022.960720

Ejemplares similares

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
por: Montaudon, Elodie, et al.
Publicado: (2020)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023)

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2017)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia
por: Adachi, Yoshiya, et al.
Publicado: (2017)

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
por: Coussy, F., et al.
Publicado: (2020)

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
por: ter Brugge, Petra, et al.
Publicado: (2023)

A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
por: Li, Lifeng, et al.
Publicado: (2020)

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
por: Dong, Jianwen, et al.
Publicado: (2018)

Volasertib for AML: clinical use and patient consideration
por: Hao, Zhonglin, et al.
Publicado: (2015)

Strategic and Statistical Considerations on the QT Assessment of Volasertib
por: Wallenstein, Gudrun, et al.
Publicado: (2017)

Volasertib preclinical activity in high-risk hepatoblastoma
por: Kats, Dina, et al.
Publicado: (2019)

Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
por: Kobayashi, Yukio, et al.
Publicado: (2015)

HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
por: El‐Botty, Rania, et al.
Publicado: (2023)

Clinical value of R-spondins in triple-negative and metaplastic breast cancers
por: Coussy, F, et al.
Publicado: (2017)

De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor
por: Morel, Adeline, et al.
Publicado: (2019)

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
por: Jacquemetton, Julien, et al.
Publicado: (2021)

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
por: Guerrero-Zotano, Ángel, et al.
Publicado: (2023)

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
por: Bièche, Ivan, et al.
Publicado: (2021)

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
por: Awada, Ahmad, et al.
Publicado: (2015)

Chordoma of the Craniocervical Junction: Endoscopic Endonasal Approach
por: Voormolen, Eduard H., et al.
Publicado: (2019)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis
por: Kumar, Shiv, et al.
Publicado: (2015)

Re-investigating PLK1 inhibitors as antimitotic agents
por: Delacour, Quentin, et al.
Publicado: (2017)

Editorial: Chordoma: advances in biology and clinical management
por: Gardner, Paul, et al.
Publicado: (2023)

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023)

Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials
por: Chateau-Joubert, Sophie, et al.
Publicado: (2021)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Ectopic Recurrence of Skull Base Chordoma after Proton Therapy
por: Santegoeds, René G. C., et al.
Publicado: (2022)

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
por: Lin, C-C, et al.
Publicado: (2014)

Anterolateral Approach with Endoscopic Assistance for Resection of a Craniovertebral Junction Chordoma
por: Champagne, Pierre-Olivier, et al.
Publicado: (2019)

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia
por: Gopalakrishnan, Bhavani, et al.
Publicado: (2018)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vhh4l7el20id10307foe5ckiht